For the year ending 2025-12-31, PMN had -$7,174,611 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -39,719,147 |
| Share-based compensation expense | 857,628 |
| Change in fair value of financial instruments | 5,592 |
| Prepaid expenses and other current assets | -2,555,126 |
| Accounts payable | 805,952 |
| Accrued liabilities | 7,387,454 |
| Net cash used in operating activities | -28,118,579 |
| Purchase of short-term investments | 33,753 |
| Maturity of short-term investment | 33,051 |
| Net cash used in investing activities | -702 |
| Proceeds from issuance of common shares pursuant to 2025 and 2024 atm offering, respectively, net of issuance costs | 708,468 |
| Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | 697,658 |
| Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | 8,391,027 |
| Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July282025Exercise Of Discounted Warrants And Pipe Offering | 11,144,467 |
| Proceeds from exercise of pre-funded warrants | 3,050 |
| Net cash provided by financing activities | 20,944,670 |
| Net (decrease) increase in cash | -7,174,611 |
| Cash at beginning of period | 13,291,167 |
| Cash at end of period | 6,116,556 |
ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. (PMN)